{"protocolSection":{"identificationModule":{"nctId":"NCT01104155","orgStudyIdInfo":{"id":"E7389-G000-205"},"organization":{"fullName":"Eisai Inc.","class":"INDUSTRY"},"briefTitle":"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer","officialTitle":"The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2018-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2011-04-07","type":"ACTUAL"},"completionDateStruct":{"date":"2017-01-18","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-12","studyFirstSubmitQcDate":"2010-04-13","studyFirstPostDateStruct":{"date":"2010-04-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-12-22","resultsFirstSubmitQcDate":"2016-12-22","resultsFirstPostDateStruct":{"date":"2017-02-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-16","lastUpdatePostDateStruct":{"date":"2023-06-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eisai Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["NSCLC","Eribulin Mesylate","Erlotinib"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":123,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"eribulin mesylate, 21 day cycle","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: eribulin mesylate + erlotinib"]},{"label":"eribulin mesylate, 28 day cycle","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: eribulin mesylate + erlotinib"]}],"interventions":[{"type":"DRUG","name":"eribulin mesylate + erlotinib","description":"21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.","armGroupLabels":["eribulin mesylate, 21 day cycle"]},{"type":"DRUG","name":"eribulin mesylate + erlotinib","description":"28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.","armGroupLabels":["eribulin mesylate, 28 day cycle"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants whose best overall response (BOR) was either a confirmed complete response (CR) or a partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria for target lesions assessed by computed tomography (CT) or magnetic resonance imaging (MRI) and based on investigator assessment. CRs and PRs had to be confirmed by a repeat assessment of response (CR or PR) separated by at least 4 weeks (28 days). CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 millimeters. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR and the corresponding 95% two-sided confidence intervals (CI) were estimated for each treatment regimen using the Clopper-Pearson method for calculating the exact binomial CI. (CR + PR)","timeFrame":"From date of first dose of study drug until, or up to the date of data cutoff (07 Apr 2011)"}],"secondaryOutcomes":[{"measure":"Duration of Response (DOR)","description":"DOR was assessed for participants with a BOR of CR or PR, and was defined as the time from first documented evidence of CR or PR (whichever status was recorded first) until the first documented sign of disease progression or death (due to any cause), whichever was first. DOR was defined for participants with a confirmed CR or PR. For participants in the subset of responders who did not progress or die, duration of response was censored. DOR was analyzed using the Kaplan-Meier method.","timeFrame":"From date of first document CR or PR (whichever was recorded first) until first documentation of disease progression or death due to any cause, or up to data cutoff (31 May 2013) up to 3.25 years"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was measured as the time from the date of first administration of study treatment until the first documentation of disease progression or death (due to any cause), whichever occurred first, as determined by investigator assessment based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. For participants who did not have an event (i.e. those who had not progressed, and were alive at the date of data cut-off or lost to Follow-up), progression-free survival was censored. Participants who did not progress in their disease were censored on the date of their last tumor assessment preceding the start of any additional anticancer therapy. PFS was analyzed using the Kaplan-Meier method.","timeFrame":"From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first), or up to data cutoff (31 May 2013) up to 3.25 years"},{"measure":"Disease Control Rate (DCR)","description":"DCR was defined as the percentage of participants who had a BOR of CR or PR, or stable disease (SD; duration of SD lasted for at least 7 weeks). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD was to be greater than or equal to 7 weeks (49 days). A participant's tumor assessment had to be at least 7 weeks following the randomization date to be consider SD. DCR and the corresponding exact Clopper-Pearson 95% CI were computed by treatment regimen. (CR + PR + SD)","timeFrame":"From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (31 May 2013), up to approximately 3.25 years"},{"measure":"Overall Survival (OS)","description":"OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date. In the absence of confirmation of death, participants were censored either at the date that the participant was last known to be alive or the date of study cutoff, whichever came first. OS and the corresponding 2-sided 95% CI was analyzed using the Kaplan-Meier method.","timeFrame":"From date of first dose of study drug until date of death from any cause or up to data cutoff (31 May 2013), up to approximately 3.25 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Histologically confirmed non-small cell lung cancer (NSCLC)\n* At least one prior platinum-based doublet anti-cancer treatment for recurrent or advanced NSCLC\n* Disease progression during or after the last anti-cancer therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2\n* Serum creatinine less than or equal to 2.0 mg/dL or creatinine clearance 40 mL/min according to Cockcroft and Gault formula:\n* Absolute neutrophil count greater than or equal to 1.5 x 10\\^9/L, hemoglobin greater than or equal to 10 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10\\^9/L\n* Total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN (in the case of liver metastases less than or equal to 5 times ULN). In case AP is greater than 3 times ULN (in absence of liver metastases) or greater than 5 times ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.\n* At least one lesion of greater than or equal to 1.5 cm in longest diameter for non-lymph nodes or greater than or equal to 1.5 cm in shortest diameter for lymph nodes which is serially measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.17\n\n  * Males and females, age greater than or equal to 18 years\n  * Provide written informed consent\n  * Are willing and able to comply with all aspects of the protocol\n  * Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (Beta-hCG) at Visit 1 (Screening) and a negative urine pregnancy test prior to starting study drug (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine device (IUD), or have a vasectomised partner) having starting for at least one menstrual cycle prior to starting study drugs and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.\n* Male subjects who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drugs and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).\n\nExclusion criteria:\n\n* Prior therapy with eribulin or an tyrosine kinase inhibitor of the epidermal growth factor receptor\n* Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued steroids for this indication for greater than or equal to 4 weeks before starting study treatment. Symptoms attributed to brain metastases must be stable for greater than or equal to 4 weeks before starting study treatment; radiographic stability should be determined by comparing contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) brain scan performed during screening to a prior scan performed 4 weeks earlier.\n* Existing anti-cancer therapy-related toxicities of grade greater than or equal to 2, other than any grade of alopecia or grade less than or equal to 2 neuropathy, which are acceptable\n* Current smokers who will not stop smoking one week prior to treatment and during the study\n* History of congestive heart failure with New York Heart Association (NYHA) Grade greater than II, unstable angina, myocardial infarction within the past 6 months, serious cardiac arrhythmia\n* Electrocardiogram with QTc interval greater than or equal to 500 msec based upon Bazett's formula (QTcB)\n* Females who are pregnant (positive Beta-hCG test) or breastfeeding\n* Subject with hypersensitivity to eribulin and /or erlotinib or any of the excipients\n* Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors\n* Subjects who are known to be human immunodeficiency virus (HIV) positive, because the neutropenia caused by the study treatments may make such subjects particularly susceptible to infection\n* Subjects with active viral hepatitis (A, B, or C) as demonstrated by positive serology\n* Radiotherapy, chemotherapy, biological therapy or investigational agents within 2 weeks prior to start of study treatment\n* Meningeal carcinomatosis\n* History of drug or alcohol dependency or abuse within approximately the last 2 years\n* Medically unfit to receive the study drug or unsuitable for any other reason according to investigator judgment\n* Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject's ability to safely complete the study\n* Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"city":"Bessemer","state":"Alabama","country":"United States","geoPoint":{"lat":33.40178,"lon":-86.95444}},{"city":"Birmingham","state":"Alabama","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"city":"Beverly Hills","state":"California","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"city":"La Jolla","state":"California","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"city":"Aurora","state":"Colorado","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"city":"Boulder","state":"Colorado","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"city":"Colorado Springs","state":"Colorado","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"city":"Denver","state":"Colorado","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"city":"Lakewood","state":"Colorado","country":"United States","geoPoint":{"lat":39.70471,"lon":-105.08137}},{"city":"Littleton","state":"Colorado","country":"United States","geoPoint":{"lat":39.61332,"lon":-105.01665}},{"city":"Lone Tree","state":"Colorado","country":"United States","geoPoint":{"lat":39.55171,"lon":-104.8863}},{"city":"Longmont","state":"Colorado","country":"United States","geoPoint":{"lat":40.16721,"lon":-105.10193}},{"city":"Parker","state":"Colorado","country":"United States","geoPoint":{"lat":39.5186,"lon":-104.76136}},{"city":"Thornton","state":"Colorado","country":"United States","geoPoint":{"lat":39.86804,"lon":-104.97192}},{"city":"Washington D.C.","state":"District of Columbia","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"city":"Ocala","state":"Florida","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"city":"Port Saint Lucie","state":"Florida","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"city":"Kansas City","state":"Kansas","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"city":"Overland Park","state":"Kansas","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"city":"Shawnee Mission","state":"Kansas","country":"United States","geoPoint":{"lat":39.02,"lon":-94.66583}},{"city":"Detroit","state":"Michigan","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"city":"Columbia","state":"Missouri","country":"United States","geoPoint":{"lat":38.95171,"lon":-92.33407}},{"city":"Jefferson City","state":"Missouri","country":"United States","geoPoint":{"lat":38.5767,"lon":-92.17352}},{"city":"Kansas City","state":"Missouri","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"city":"Lee's Summit","state":"Missouri","country":"United States","geoPoint":{"lat":38.91084,"lon":-94.38217}},{"city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"city":"Las Vegas","state":"Nevada","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"city":"Elizabeth City","state":"North Carolina","country":"United States","geoPoint":{"lat":36.2946,"lon":-76.25105}},{"city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"city":"Tualatin","state":"Oregon","country":"United States","geoPoint":{"lat":45.38401,"lon":-122.76399}},{"city":"Philadelphia","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"city":"East Providence","state":"Rhode Island","country":"United States","geoPoint":{"lat":41.81371,"lon":-71.37005}},{"city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"city":"Fort Worth","state":"Texas","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"city":"Garland","state":"Texas","country":"United States","geoPoint":{"lat":32.91262,"lon":-96.63888}},{"city":"Plano","state":"Texas","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"city":"Arlington","state":"Virginia","country":"United States","geoPoint":{"lat":38.88101,"lon":-77.10428}},{"city":"Chesapeake","state":"Virginia","country":"United States","geoPoint":{"lat":36.81904,"lon":-76.27494}},{"city":"Fairfax","state":"Virginia","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"city":"Gainesville","state":"Virginia","country":"United States","geoPoint":{"lat":38.79567,"lon":-77.61388}},{"city":"Hampton","state":"Virginia","country":"United States","geoPoint":{"lat":37.02987,"lon":-76.34522}},{"city":"Leesburg","state":"Virginia","country":"United States","geoPoint":{"lat":39.11566,"lon":-77.5636}},{"city":"Newport News","state":"Virginia","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}},{"city":"Norfolk","state":"Virginia","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"city":"Virginia Beach","state":"Virginia","country":"United States","geoPoint":{"lat":36.85293,"lon":-75.97799}},{"city":"Williamsburg","state":"Virginia","country":"United States","geoPoint":{"lat":37.2707,"lon":-76.70746}},{"city":"Winchester","state":"Virginia","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"city":"Woodbridge","state":"Virginia","country":"United States","geoPoint":{"lat":38.65817,"lon":-77.2497}},{"city":"Spokane","state":"Washington","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"city":"Vancouver","state":"Washington","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Kuantan","state":"Pahang","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"city":"George Town","country":"Malaysia","geoPoint":{"lat":5.41123,"lon":100.33543}},{"city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Goyang","country":"South Korea","geoPoint":{"lat":36.21689,"lon":127.19731}},{"city":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Taichung","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Bangkok","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"city":"Chiang Mai","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"city":"Lampang","country":"Thailand","geoPoint":{"lat":18.29232,"lon":99.49277}},{"city":"Songkhla","country":"Thailand","geoPoint":{"lat":7.19882,"lon":100.5951}}]},"referencesModule":{"references":[{"pmid":"24827127","type":"DERIVED","citation":"Mok TS, Geater SL, Iannotti N, Thongprasert S, Spira A, Smith D, Lee V, Lim WT, Reyderman L, Wang B, Gopalakrishna P, Garzon F, Xu L, Reynolds C. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Ann Oncol. 2014 Aug;25(8):1578-84. doi: 10.1093/annonc/mdu174. Epub 2014 May 14."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"164 participants were screened. Of these 164 participants, 41 were screening failures, and 123 were randomized into the study. Of the 41 screen failures, 31 participants failed to meet inclusion or exclusion criteria and 10 were excluded due to adverse events, withdrew consent, and other reasons.","groups":[{"id":"FG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"FG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"18"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Participant choice","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal of consent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"BG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"123"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.7","spread":"11.08"},{"groupId":"BG001","value":"63.1","spread":"10.05"},{"groupId":"BG002","value":"62.4","spread":"10.57"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Gender","categories":[{"title":"Male","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"66"}]},{"title":"Female","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants whose best overall response (BOR) was either a confirmed complete response (CR) or a partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria for target lesions assessed by computed tomography (CT) or magnetic resonance imaging (MRI) and based on investigator assessment. CRs and PRs had to be confirmed by a repeat assessment of response (CR or PR) separated by at least 4 weeks (28 days). CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to less than 10 millimeters. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR and the corresponding 95% two-sided confidence intervals (CI) were estimated for each treatment regimen using the Clopper-Pearson method for calculating the exact binomial CI. (CR + PR)","populationDescription":"Full analysis set (FAS) (Intent-to-treat population) included all participants who took at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From date of first dose of study drug until, or up to the date of data cutoff (07 Apr 2011)","groups":[{"id":"OG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"OG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"5.6","upperLimit":"23.5"},{"groupId":"OG001","value":"16.7","lowerLimit":"8.3","upperLimit":"28.5"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.204","statisticalMethod":"1-sided exact binomial","statisticalComment":"Based on a one-sided exact binomial test compared to 9%."},{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.041","statisticalMethod":"1-sided exact binomial"}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"DOR was assessed for participants with a BOR of CR or PR, and was defined as the time from first documented evidence of CR or PR (whichever status was recorded first) until the first documented sign of disease progression or death (due to any cause), whichever was first. DOR was defined for participants with a confirmed CR or PR. For participants in the subset of responders who did not progress or die, duration of response was censored. DOR was analyzed using the Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of first document CR or PR (whichever was recorded first) until first documentation of disease progression or death due to any cause, or up to data cutoff (31 May 2013) up to 3.25 years","groups":[{"id":"OG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"OG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"2.7","upperLimit":"NA","comment":"Not evaluable"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.6","upperLimit":"NA","comment":"Not evaluable"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was measured as the time from the date of first administration of study treatment until the first documentation of disease progression or death (due to any cause), whichever occurred first, as determined by investigator assessment based on RECIST v1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. For participants who did not have an event (i.e. those who had not progressed, and were alive at the date of data cut-off or lost to Follow-up), progression-free survival was censored. Participants who did not progress in their disease were censored on the date of their last tumor assessment preceding the start of any additional anticancer therapy. PFS was analyzed using the Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first), or up to data cutoff (31 May 2013) up to 3.25 years","groups":[{"id":"OG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"OG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"1.9","upperLimit":"4.7"},{"groupId":"OG001","value":"3.8","lowerLimit":"3.3","upperLimit":"5.5"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"DCR was defined as the percentage of participants who had a BOR of CR or PR, or stable disease (SD; duration of SD lasted for at least 7 weeks). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD was to be greater than or equal to 7 weeks (49 days). A participant's tumor assessment had to be at least 7 weeks following the randomization date to be consider SD. DCR and the corresponding exact Clopper-Pearson 95% CI were computed by treatment regimen. (CR + PR + SD)","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first) or up to data cutoff (31 May 2013), up to approximately 3.25 years","groups":[{"id":"OG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"OG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","lowerLimit":"34.9","upperLimit":"60.6"},{"groupId":"OG001","value":"63.3","lowerLimit":"49.9","upperLimit":"75.4"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the length of time in months from the date of first administration of study drug until the date of death from any cause, and was based on the data cutoff date. In the absence of confirmation of death, participants were censored either at the date that the participant was last known to be alive or the date of study cutoff, whichever came first. OS and the corresponding 2-sided 95% CI was analyzed using the Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of first dose of study drug until date of death from any cause or up to data cutoff (31 May 2013), up to approximately 3.25 years","groups":[{"id":"OG000","title":"Eribulin Mesylate Plus Erlotinib, 21 Day Regimen","description":"Eribulin mesylate was given at a dose of 2 mg/m\\^2 as a 2 to 5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib was given orally once daily, one hour before or two hours after the ingestion of food, on Days 2 to 16 of a 21-day cycle."},{"id":"OG001","title":"Eribulin Mesylate Plus Erlotinib, 28 Day Regimen","description":"Eribulin mesylate was given at a dose of 1.4 mg/m\\^2 as a 2 to 5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15 to 28 of a 28-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"6.3","upperLimit":"11.0"},{"groupId":"OG001","value":"8.5","lowerLimit":"6.2","upperLimit":"13.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From date of administration of first dose up to 30 days after the last dose, or up to approximately 6 years 11 months","description":"Treatment-emergent adverse events (TEAEs) included adverse events that occurred from the first dose of study drug to 30 days after the last dose of study drug, or that were present prior to the first dose of study drug administration but worsened in severity during the study.","eventGroups":[{"id":"EG000","title":"Eribulin Mesylate, 21 Day Cycle","description":"Eribulin mesylate + Erlotinib: 21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.","deathsNumAffected":59,"deathsNumAtRisk":63,"seriousNumAffected":38,"seriousNumAtRisk":63,"otherNumAffected":61,"otherNumAtRisk":63},{"id":"EG001","title":"Eribulin Mesylate, 28 Day Cycle","description":"Eribulin mesylate + Erlotinib: 28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.","deathsNumAffected":51,"deathsNumAtRisk":60,"seriousNumAffected":27,"seriousNumAtRisk":60,"otherNumAffected":60,"otherNumAtRisk":60}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Asthenia + Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Haematoma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":60}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":63},{"groupId":"EG001","numAffected":25,"numAtRisk":60}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":8,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":63},{"groupId":"EG001","numAffected":25,"numAtRisk":60}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":63},{"groupId":"EG001","numAffected":21,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":63},{"groupId":"EG001","numAffected":26,"numAtRisk":60}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":63},{"groupId":"EG001","numAffected":23,"numAtRisk":60}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":63},{"groupId":"EG001","numAffected":11,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":63},{"groupId":"EG001","numAffected":16,"numAtRisk":60}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Asthenia + Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":63},{"groupId":"EG001","numAffected":33,"numAtRisk":60}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":63},{"groupId":"EG001","numAffected":30,"numAtRisk":60}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":63},{"groupId":"EG001","numAffected":9,"numAtRisk":60}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":63},{"groupId":"EG001","numAffected":24,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":63},{"groupId":"EG001","numAffected":9,"numAtRisk":60}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Arthralgia + Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":63},{"groupId":"EG001","numAffected":8,"numAtRisk":60}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":63},{"groupId":"EG001","numAffected":14,"numAtRisk":60}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":63},{"groupId":"EG001","numAffected":12,"numAtRisk":60}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":63},{"groupId":"EG001","numAffected":11,"numAtRisk":60}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":63},{"groupId":"EG001","numAffected":16,"numAtRisk":60}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":63},{"groupId":"EG001","numAffected":8,"numAtRisk":60}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":63},{"groupId":"EG001","numAffected":15,"numAtRisk":60}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":63},{"groupId":"EG001","numAffected":9,"numAtRisk":60}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":63},{"groupId":"EG001","numAffected":7,"numAtRisk":60}]},{"term":"Peripheral Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":10,"numAtRisk":60}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":6,"numAtRisk":60}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":9,"numAtRisk":60}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":63},{"groupId":"EG001","numAffected":14,"numAtRisk":60}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Breath sounds abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":5,"numAtRisk":60}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":60}]},{"term":"Neuropathy based on broad MedDRA SMQ","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Neuropathy based on broad MedDRA SMQ","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":63},{"groupId":"EG001","numAffected":12,"numAtRisk":60}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":4,"numAtRisk":60}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":2,"numAtRisk":60}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Eisai Medical Information","organization":"Eisai Inc.","email":"esi_oncmedinfo@eisai.com","phone":"1-888-422-4743"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C490954","term":"eribulin"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}